CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,975.00
-6.00 (-0.30%)
Aug 14, 2025, 3:30 PM KST
-0.30%
Market Cap290.76B
Revenue (ttm)96.91B
Net Income (ttm)-1.13B
Shares Out147.22M
EPS (ttm)-20.99
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume339,431
Average Volume630,363
Open1,967.00
Previous Close1,981.00
Day's Range1,967.00 - 2,005.00
52-Week Range1,590.00 - 3,345.00
Beta0.78
RSI47.68
Earnings DateAug 13, 2025

About CMG Pharmaceutical

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutic... [Read more]

Sector Healthcare
Founded 2001
Employees 229
Stock Exchange KOSDAQ
Ticker Symbol 058820
Full Company Profile

Financial Performance

In 2024, CMG Pharmaceutical's revenue was 99.10 billion, an increase of 5.53% compared to the previous year's 93.91 billion. Earnings were 2.69 billion, a decrease of -58.26%.

Financial Statements

News

There is no news available yet.